Skip to content

CLLS

Cellectis SA

NASDAQ · Healthcare · Biotechnology · FR

$0.91
−12.40%
Ask drillr

Year over year

Reported trailing growth

Revenue
+0.5%
EBITDA
-83.4%
EBIT
-36.8%
EPS
-12.4%
Free cash flow
-20.4%
Operating cash flow
-25.6%

Forward estimates

Based on analyst estimates

Revenue
+99.5%
EBITDA
-24.9%
EPS
-46.9%

Three-year CAGR

Revenue
+56.1%
EBITDA
—
EBIT
+44.5%
Net income
-83.9%
EPS
-65.9%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026